Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Sensex up 100 pts, Nifty above 9950; Dr Reddy’s Labs spikes 9%

Dr Reddy’s Laboratories shares rallied more than 9 percent intraday after Settlement Agreement with US-based Vivus to resolve a long-pending patent litigation related to anti-obesity pill (or weight management capsules) Qsymia.
The Settlement agreement permits the company to begin selling a generic version of Qsymia on June 1, 2025, or earlier under certain circumstances. In the event of a launch earlier than June 1, 2025, Vivus will receive a royalty on sales of the generic version of Qsymia.
Qysmia is a combination of phentermine and topiramate extended-release sold in capsule form. The drug is used to manage chronic overweight in adults with obesity symptoms.
 The drug has gross sales of around USD 73.6 million in 2016.

For more information and best Stock futures tips Call us ✆ – 0731-6642300 or Visit

Connect with our social media sites

Follow @Epic_Research

This post first appeared on Stock Market Tips, please read the originial post: here

Share the post

Sensex up 100 pts, Nifty above 9950; Dr Reddy’s Labs spikes 9%


Subscribe to Stock Market Tips

Get updates delivered right to your inbox!

Thank you for your subscription